Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pharm Biomed Anal ; 48(3): 708-15, 2008 Nov 04.
Artigo em Inglês | MEDLINE | ID: mdl-18755563

RESUMO

During the process development of montelukast sodium, three polar impurities and one non-polar impurity with respect to montelukast sodium were detected by simple reverse phase high-performance liquid chromatography (HPLC). Initially, all the four impurities were identified by the liquid chromatography-mass spectrometry (LC-MS) data and out of four impurities, three have been prepared by the synthetic method and remaining one is isolated by preparative HPLC. Based on the spectral data (IR, (1)H NMR, (13)C NMR and MS), the structure of these impurities 1-4 were characterised as 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropane acetamide (impurity-1), {1-[1-{3-[2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-(2-isopropenyl-phenyl)-propylsulfanylmethyl]-cyclopropyl}-acetic acid (impurity-2), 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethyl]phenyl-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (impurity-3) and 1-[[[(1R)-1-[3-[(1E)-2-(2-quinolinyl)ethenyl]phenyl-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (impurity-4).


Assuntos
Acetatos/análise , Acetatos/síntese química , Acetatos/isolamento & purificação , Contaminação de Medicamentos , Antagonistas de Leucotrienos/análise , Espectrometria de Massas/métodos , Quinolinas/análise , Quinolinas/síntese química , Quinolinas/isolamento & purificação , Acetatos/química , Cromatografia Líquida de Alta Pressão/métodos , Ciclopropanos , Estrutura Molecular , Ressonância Magnética Nuclear Biomolecular/métodos , Quinolinas/química , Espectrofotometria Infravermelho/métodos , Espectroscopia de Infravermelho com Transformada de Fourier/métodos , Sulfetos
2.
J Pharm Biomed Anal ; 29(1-2): 355-60, 2002 Jun 20.
Artigo em Inglês | MEDLINE | ID: mdl-12062697

RESUMO

Two unknown impurities in rofecoxib bulk drug at levels below 0.1% were detected by a simple isocratic reverse phase high performance liquid chromatography (HPLC). These impurities were isolated from crude sample of rofecoxib using reverse phase preparative HPLC. (1)H, (13)C and Mass spectroscopic investigations revealed the structures of the impurities as 4-[4-(methylsulphonyl)phenyl]-3-phenyl-5-hydroxyfuran-2-one (I) and 4-[4-(methylsulphonyl)phenyl]-3-phenyl-2,5-furandione (II), respectively. These structures were further confirmed by prepared synthetic standards of the impurities. The tentative mechanism for the formation of these impurities was discussed.


Assuntos
Anti-Inflamatórios não Esteroides/análise , Cromatografia Líquida de Alta Pressão/métodos , Contaminação de Medicamentos , Lactonas/análise , Espectrometria de Massas , Espectroscopia de Infravermelho com Transformada de Fourier , Sulfonas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...